Performance of serum C-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence population by Wilson, Douglas et al.
Performance of Serum C-Reactive Protein as a Screening
Test for Smear-Negative Tuberculosis in an Ambulatory
High HIV Prevalence Population
Douglas Wilson1*, Motasim Badri2, Gary Maartens3
1Department of Medicine, Edendale Hospital, Pietermaritzburg, University of KwaZulu-Natal, KwaZulu-Natal, South Africa, 2Department of Medicine, University of Cape
Town, Cape Town, South Africa, 3Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Abstract
Background: Delayed diagnosis has contributed to the high mortality of sputum smear-negative tuberculosis (SNTB) in high
HIV prevalence countries. New diagnostic strategies for SNTB are urgently needed. C-reactive protein (CRP) is a non-specific
inflammatory protein that is usually elevated in patients with tuberculosis, but its role in the diagnosis of tuberculosis is
uncertain.
Methodology/Principal Findings: To determine the diagnostic utility of CRP we prospectively evaluated the performance of
CRP as a screening test for SNTB in symptomatic ambulatory tuberculosis suspects followed up for 8 weeks in KwaZulu-
Natal, South Africa. Confirmed tuberculosis was defined as positive culture or acid-fast bacilli with granulomata on
histology, and possible tuberculosis as documented response to antitubercular therapy. The CRP quotient was defined as a
multiple of the upper limit of normal of the serum CRP result. Three hundred and sixty four participants fulfilled entry
criteria: 135 (37%) with confirmed tuberculosis, 114 (39%) with possible tuberculosis, and 115 (24%) without tuberculosis.
The median CRP quotient was 15.4 (IQR 7.2; 23.3) in the confirmed tuberculosis group, 5.8 (IQR 1.4; 16.0) in the group with
possible tuberculosis, and 0.7 (IQR 0.2; 2.2) in the group without tuberculosis (p,0.0001). The CRP quotient above the upper
limit of normal had sensitivity 0.98 (95% CI 0.94; 0.99), specificity 0.59 (95% CI 0.50; 0.68), positive predictive value 0.74 (95%
CI 0.67; 0.80), negative predictive value 0.96 (95% CI 0.88; 0.99), and diagnostic odds ratio 63.7 (95% CI 19.1; 212.0) in the
confirmed tuberculosis group compared with the group without tuberculosis. Higher CRP quotients improved specificity at
the expense of sensitivity.
Significance: In high HIV prevalence settings a normal CRP could be a useful test in combination with clinical evaluation to
rule out tuberculosis in ambulatory patients. Point-of-care CRP should be further evaluated in primary care clinics.
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Introduction
The HIV epidemic has substantially increased the incidence of
tuberculosis, and especially smear-negative tuberculosis (SNTB), in
high prevalence resource-limited settings [1–3]. Tuberculosis is a
curable infection yet remains the leading cause of death in sub-
Saharan Africa [4–6], in part due to delayed diagnosis. New
diagnostic tests for tuberculosis are urgently required and are
under evaluation, but currently sputum microscopy is the only
widely available diagnostic test for tuberculosis [7].
C-reactive protein (CRP) is a non-specific acute phase serum
protein that is elevated in HIV seropositive and seronegative
patients with tuberculosis [8–15]. Recently, CRP has been
proposed as a candidate biomarker for active infection with
Mycobacterium tuberculosis [16]. Point-of-care CRP testing has been
shown to be of use in the clinical evaluation of respiratory tract
infections in adults [17–19] and in the evaluation of fever in
children [20–22]. Additionally, an elevated point-of-care CRP has
been used as an indication to initiate antibiotic therapy [18]. The
diagnostic utility of CRP in smear-negative tuberculosis suspects in
a high HIV prevalence setting is unknown.
We evaluated serum CRP in sputum smear-negative tubercu-
losis suspects in the Umgungundlovu District, KwaZulu-Natal,
South Africa.
Methods
Ethics statement
The study was approved by the Biomedical Research Ethics
Committees of the University of KwaZulu-Natal and the University
of Cape Town, and by the KwaZulu-Natal Department of Health.
All participants gave written informed consent prior to enrolment.
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Study setting
Tuberculosis suspects were enrolled between June 2005 and
February 2007 from primary care clinics in the uMgungundlovu
District, KwaZulu-Natal, South Africa. The district is represen-
tative of the high tuberculosis and HIV burden in southern Africa:
in 2007 the HIV prevalence in public sector antenatal clinics was
40.4%, and the estimated 2006 annual incidence of tuberculosis
was 1,094 cases/100,000 [23,24].
Study population
Consecutive adults older than 18 years who gave informed
consent were eligible for inclusion if they were being worked up by
the primary care clinic as TB suspects. Inclusion criteria were one
or more symptoms compatible with tuberculosis for .2 weeks
(cough, weight loss, loss of appetite, haemoptysis, fevers and chills,
drenching night sweats, fatigue, chest pain, haemoptysis, shortness
of breath, swollen lymph nodes, abdominal swelling), and two or
more sputum smears negative for acid-fast bacilli (AFB) or unable
to produce sputum. Exclusion criteria were: missing baseline CRP,
not completing eight weeks of follow-up, Karnofsky performance
score ,40, tuberculous meningitis, Pneumocystis jirovecii pneumonia,
more than one week of antitubercular therapy, less than three
months of antiretroviral therapy, or a flouroquinolone within the
past 6 months.
Study procedures
Eligible participants were assessed for evidence of SNTB using a
standardized protocol that included chest radiograph in all cases,
and abdominal and pericardial ultrasound if indicated. These
clinical and radiological data were used to assign participants
either to antitubercular therapy or observation using pre-specified
criteria. Participants were assigned to antitubercular therapy if
clinicians identified a focal process compatible with tuberculosis
either on physical examination or radiographic imaging using
modifications of previously validated case definitions [9].
At enrolment at least two relevant specimens were taken for
mycobacterial culture. Sputum induction with hypertonic saline
and an ultrasonic nebuliser was performed in all participants. All
specimens sent for mycobacterial culture were stained for acid-fast
bacilli using fluorescent microscopy and cultured in liquid culture
media (BACTECTM MGITTM BD, Sparks, MD). Positive cultures
were identified as Mycobacterium tuberculosis using the niacin test. All
laboratory investigations were performed in accordance with
manufacturers’ instructions at accredited laboratories by techni-
cians registered with the Health Professions Council of South
Africa. External quality assurance for sputum smears was routinely
undertaken by the National Health Laboratory Service. Techni-
cians evaluating specimens for acid-fast bacilli and positive
mycobacterial cultures did not have access to CRP results. Serum
CRP was measured with the Olympus AU640 (normal range
0–8 mg/L) for the initial 182 participants; and the Dade
Dimension RXL (normal range 0–5 mg/L) for the subsequent
182 participants.
Participants were reviewed 2, 4 and 8 weeks after enrolment.
Patients in the observation group who had a positive AFB smear or
mycobacterial culture, or who clinically deteriorated during
follow-up were started on antitubercular therapy and reviewed
for an alternative diagnosis. Participants in the treatment group
who deteriorated were reviewed for an alternative diagnosis. At
each visit data were collected on weight, haemoglobin concentra-
tion, Karnofsky performance score and symptoms score (number
of tuberculosis-related symptoms rated ‘much better’ or ‘resolved’
dividing by the total number of tuberculosis-related symptoms
present at enrolment).
Diagnosis of tuberculosis
Participants were classified into one of three groups: i) confirmed
tuberculosis (at least one clinical specimen culture-positive for
Mycobacterium tuberculosis or AFB with granulomata on histology); ii)
possible tuberculosis (focal disease process compatible with
tuberculosis detected on clinical examination or imaging, or a
wasting syndrome, and clinical response to anti-tubercular therapy);
iii) no tuberculosis (culture-negative, without a focal process or
wasting and with a clinically stable course over an eight-week
observation period, or an alternative diagnosis made, or no response
to empiric antitubercular therapy). Research clinicians had access to
the CRP result only after the decision whether or not to initiate
antitubercular therapy had been made. Clinical response to
antitubercular therapy was defined as meeting two or more criteria
at week 8: i) weight gain.5%; ii) haemoglobin increase.1.0 g/dL;
iii) increase in Karnofsky score.20 (or.10 if baseline score was 80
or 90); and iv) symptom score .0.5 (i.e., at least half of the
symptoms much better or resolved). We have previously evaluated
these criteria [9].
Data analysis
Data were entered into a Microsoft Access database and
analysed using Analyse-it for Microsoft Excel (version 2.11). In
order to correct for the differing normal ranges CRP results were
expressed as the quotient of the absolute CRP value divided by the
upper limit of normal for the assay. In order to determine the most
useful cut-off for the CRP quotient the performance characteristics
were calculated for measurements that were either normal or
raised (CRP quotient .16 upper limit of normal [ULN]), and
either greater than or less than 2.56, 56 and 106 ULN.
Categorical data were compared between different groups using
the Pearson chi-squared test, and odds ratio using Fisher’s exact
test. Accuracy of probability estimates were determined by
calculating ninety five percent confidence intervals (95% CI).
Distribution of continuous data was determined using the Shapiro-
Wilk test, difference in medians between two groups using the
Mann-Whitney test, and difference in medians between more than
two groups using the Kruskal-Wallis test.
Results
Cohort characteristics
Five hundred and four patients were screened, and 364
participants evaluated. Participant flow and final diagnosis is
summarized in Figure 1. The clinical characteristics of the
participants are shown in Table 1. Two hundred (55%)
participants were HIV seropositive, 39 (11.%) HIV seronegative,
and 125 (34%) declined an HIV test. The median CD4 T-
lymphocyte count was 143 cells/mL (interquartile range [IQR] 78;
248) in the 136 HIV seropositive participants who had the test
during the eight week follow-up period.
Tuberculosis diagnosis
One hundred and thirty five (37%) participants were classified
as having confirmed tuberculosis (132 on culture and three on
histology), and 114 (31%) had possible tuberculosis (including two
who were originally assigned to the observation arm, deteriorated,
and subsequently responded to antitubercular therapy). One
hundred and fifteen participants (32%) were classified as not
having tuberculosis: 68 remained stable without antitubercular
therapy for eight weeks, 26 had no response to antitubercular
therapy criteria, and 3 deteriorated on antitubercular therapy and
another diagnosis was made. Of the 249 participants diagnosed
with confirmed or possible tuberculosis 112 (45%) had pulmonary
Smear-Negative TB Screening Using CRP
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15248
disease, 63 (25%) had both pulmonary and extrapulmonary
disease and 74 (30%) had extrapulmonary disease only. Five
(1.4%) of the participants were on antiretroviral therapy for .3
months (two with confirmed tuberculosis and three without
tuberculosis).
CRP quotient by tuberculosis diagnosis
The median CRP quotient in the confirmed tuberculosis group
was 15.4 (IQR 7.2; 23.3), 5.8 (IQR 1.4; 16.0) in the group with
possible tuberculosis, and 0.7 (IQR 0.2; 2.2) in the group without
tuberculosis (p,0.0001). Three (2%), 23 (20%) and 68 (59%)
participants had a normal CRP in these three groups respectively
(p,0.0001).
Of the 135 participants diagnosed with confirmed tuberculosis
116 (86%) were diagnosed with a focal disease process consistent
with tuberculosis: 36 had pulmonary disease; 33 had both
pulmonary and extrapulmonary disease; and 47 had extrapulmo-
nary disease. The median CRP quotient in these three groups was
12.4 (IQR 7.1–17.4), 18.2 (IQR 12.6–27.3) and 21.6 (IQR 9.3–
27.6) (p=0.01). The 19 participants with confirmed tuberculosis
that was not diagnosed during the initial clinical evaluation had a
median CRP quotient of 7.0 (IQR 2.4–16.2) compared to the
median CRP quotient of 15.9 (IQR 9.4–24.5) in the 116
participants diagnosed with a focal process (p=0.0003).
Receiver operating curve characteristics and sensitivity/speci-
ficity decision plots for the group with confirmed tuberculosis and
for the group with confirmed and possible tuberculosis are shown
in Figure 2. Performance of the screening CRP quotient at various
levels above the upper limit of normal are shown in Tables 2–4.
The CRP quotient above the upper limit of normal had sensitivity
0.98 (95% CI 0.94; 0.99), specificity 0.59 (95% CI 0.50; 0.68),
positive predictive value 0.74 (95% CI 0.67; 0.80), negative
predictive value 0.96 (95% CI 0.88; 0.99), and diagnostic odds
ratio 63.7 (95% CI 19.1; 212.0) in the confirmed tuberculosis
group compared with the group without tuberculosis (Table 2).
The positive predictive value was highest in the analyses that
combined the confirmed and possible tuberculosis group (Table 3).
Sensitivity and negative predictive value were maintained at the
expense of the specificity and positive predictive value when the
confirmed tuberculosis group was compared with the combined
Figure 1. Participant flow chart and final diagnosis. * Reasons for exclusion (n) Not able to attend for regular review - determined during
screening visit (28) No active symptoms (17) Alternative medical diagnosis made at screening (14) Karnofsky Score ,40 (5) Pneumocystis pneumonia
(4) Informed consent not obtained (3) Sputum smear positive (3) Already on antitubercular therapy (3) Other (6).
doi:10.1371/journal.pone.0015248.g001
Table 1. Participant characteristics (n = 364).
Characteristic
Age, median (IQR), years 34.4 (29.3–42.1)
Men, n (%) 203 (57.5)
HIV seropositive, n (%) [of 239 who tested] 200 (83.7)
Prior tuberculosis treatment, n (%) 98 (26.9)
Cough .2 weeks, n (%) 341 (93.7)
Weight loss, n (%) 277 (76.1)
Anorexia, n (%) 256 (70.3)
Drenching night sweats, n (%) 248 (68.1)
Fatigue, n (%) 232 (63.7)
Fever and chills, n (%) 219 (60.2)
Chest pain, n (%) 207 (56.9)
Dyspnoea, n (%) 145 (39.8)
Haemoptysis, n (%) 40 (11.0)
Lymph node swelling, n (%) 34 (9.3)
Abdominal swelling, n (%) 4 (1.1)
Received antibiotic within 2 weeks of enrolment, n (%) 261 (71.7)
Karnofsky Performance Score, median (IQR) 70 (60–80)
Respiratory rate, median (IQR) breaths/minute 24 (20–30)
Temperature, median (IQR) uC 36.8 (36.0–37.5)
Resting heart rate, median (IQR) 100 (84–120)
Weight, median (IQR) kg 57.5 (50.6–64.8)
Body mass index, median (IQR) kg/m2 21.2 (18.9–23.6)
Haemoglobin, mean (SD) g/dL 11.1 (2.3)
doi:10.1371/journal.pone.0015248.t001
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possible tuberculosis and no tuberculosis groups (Table 4). Higher
CRP quotients improved specificity at the expense of sensitivity.
The two CRP assays used showed similar performance
characteristics in subgroup analyses of the confirmed tuberculosis
group vs. those without confirmed tuberculosis (Figure S1).
The median CRP quotient was not affected by previous
treatment for tuberculosis in the 135 participants with confirmed
tuberculosis (16.5 [IQR 11.4; 21.2] and 14.2 [IQR 7.1; 23.4] in
the participants with and without prior tuberculosis respectively,
p=0.58). Prescription of an antibiotic before enrolment did not
significantly alter the median CRP quotient in subgroup analysis
of participants with confirmed, possible and without tuberculosis
(p$0.57, data not shown).
The performance characteristics of the CRP quotient were
similar when the 54 participants without week 8 data were
included (15 [28%] with confirmed tuberculosis) in an intention to
treat analysis (Figure S2): for those with confirmed tuberculosis
versus those without confirmed tuberculosis the area under the
receiver operating curve was 0.81 (95% CI 0.77; 0.85) p,0.0001,
and sensitivity/specificity decision plot intercept rate 0.75 and
CRP quotient 7.4.
Effect of HIV status on CRP quotient
HIV status did not significantly influence the median CRP in
the three diagnostic categories (Table 5). Fifty five HIV
seropositive patients were diagnosed with confirmed tuberculosis
Figure 2. Receiver operating curves and sensitivity/specificity decision plots. A and B comparing participants with confirmed tuberculosis
vs. those with no tuberculosis (n = 250); C and D combined confirmed and possible tuberculosis vs. those with no tuberculosis (n = 364); and E and F
confirmed tuberculosis vs. those with possible tuberculosis and no tuberculosis.
doi:10.1371/journal.pone.0015248.g002
Table 2. Performance of CRP as a screening test: Confirmed tuberculosis vs. those with no tuberculosis (n = 250).
CRP quotient Sensitivity Specificity
Positive likelihood
ratio
Negative
likelihood ratio
Diagnostic odds
ratio
Positive predictive
value
Negative
predictive value
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
.16ULN 0.98 0.59 2.39 0.04 63.7 0.74 0.96
(0.94; 0.99) (0.50; 0.68) (2.29; 2.49) (0.02; 0.07) (19.1; 212.0) (0.67; 0.80) (0.88; 0.99)
$2.56ULN 0.95 0.77 4.19 0.07 62.6 0.83 0.93
(0.90; 0.98) (0.69; 0.85) (3.89; 4.52) (0.05; 0.09) (26.0; 150.5) (0.76; 0.89) (0.86; 0.97)
$56ULN 0.88 0.85 5.96 0.14 42.9 0.87 0.86
(0.81; 0.93) (0.77; 0.91) (5.30; 6.71) (0.12; 0.16) (20.6; 89.2) (0.81; 0.92) (0.78; 0.92)
$106ULN 0.69 0.93 9.90 0.33 29.6 0.92 0.72
(0.64; 0.77) (0.87; 0.97) (7.68; 12.77) (0.32; 0.35) (13.2; 66.3) (0.85; 0.96) (0.64; 0.79)
doi:10.1371/journal.pone.0015248.t002
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and had a CD4 T-lymphocyte count result. Forty had a CD4
count of ,200 cells/mL and median CRP quotient of 19.9 (IQR
12.8; 25.1), and 15 had a CD4 count $200 cells/mL and median
CRP quotient of 8.2 (IQR 6.5; 15.1) (p=0.001). Performance of
CRP quotient by HIV serostatus are shown in Table S1 and S2.
Discussion
We have shown that CRP has high sensitivity for the diagnosis
of tuberculosis in this well-defined ambulatory cohort of SNTB
suspects. Importantly, the CRP quotient was not affected by HIV
status, and in HIV seropositive participants with confirmed
tuberculosis was significantly higher in those with advanced HIV
disease. Overall, higher CRP quotients were associated with
increasing specificity and positive predictive value at the cost of
lower sensitivity and negative predictive values. However, the high
negative predictive value of any elevated CRP (0.96 for
participants with confirmed tuberculosis and 0.72 for all with
tuberculosis) suggests that a normal CRP would be useful for
ruling out tuberculosis.
Elevated CRP levels have been demonstrated in HIV infected
patients with confirmed tuberculosis [8–11] and in patients with a
clinical syndrome compatible with either pneumonia or tubercu-
losis [11–14]. Breen et al found that an elevated CRP detected
85% of proven tuberculosis cases in London, with a 29% HIV
seroprevalence in the cohort [15]. This study develops these
findings by focusing on the performance of CRP in ambulatory
SNTB suspects in a resource-limited high HIV prevalence setting
in sub-Saharan Africa. Recent data from Europe and the United
Kingdom have demonstrated the feasibility and acceptability of
using a point-of-care CRP assay in primary care settings. [18–22].
CRP may have a role in algorithms for the evaluation of SNTB in
sub-Saharan Africa where the need for novel tuberculosis
diagnostics is greatest. Screening CRP may be most effectively
used in early in diagnostic algorithms in primary care settings to
triage smear-negative tuberculosis suspects for onward referral for
chest radiograph and clinician review.
This study has several limitations. Participant enrolment was
from a single site in an area with exceptionally high prevalence of
HIV and incidence of tuberculosis. The utility of CRP in the
diagnosis of SNTB should be evaluated in other primary care
settings in sub-Saharan Africa where the prevalence of tuberculosis
and/or HIV is lower. Secondly, the research clinicians had access
to the screening CRP result during the follow-up visits and this
may have affected evaluation of the subjective components of the
response to antitubercular therapy (Karnofsky Performance Score
and symptom ratio). Third, almost all participants were not taking
antiretroviral therapy at the time of the study. CRP is elevated in
Table 3. Performance of CRP as a screening test: Combined group of confirmed or possible tuberculosis vs. those with no
tuberculosis (n = 364).
CRP quotient Sensitivity Specificity
Positive
likelihood ratio
Negative
likelihood ratio
Diagnostic odds
ratio
Positive predictive
value
Negative
predictive value
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
.16ULN 0.90 0.59 2.19 0.18 12.4 0.83 0.72
(0.85;0.93) (0.50; 0.68) (2.1; 2.3) (0.16; 0.19) (7.1; 21.5) (0.77; 0.87) (0.62; 0.81)
$2.56ULN 0.81 0.77 3.59 0.24 14.7 0.89 0.65
(0.76; 0.86) (0.69; 0.85) (3.32; 3.88) (0.23; 0.25) (8.6; 25.2) (0.84; 0.92) (0.57; 0.73)
$56ULN 0.71 0.85 4.84 0.33 14.4 0.91 0.58
(0.65; 0.77) (0.77; 0.91) (4.29; 5.45) (0.32; 0.34) (8.1; 25.9) (0.86; 0.95) (0.50; 0.65)
$10 u ULN 0.53 0.93 7.56 0.51 14.8 0.94 0.48
(0.46; 0.59) (0.87; 0.97) (5.84; 9.79) (0.50; 0.52) (6.9; 31.7) (0.89; 0.97) (0.41; 0.54)
doi:10.1371/journal.pone.0015248.t003
Table 4. Performance of CRP as a screening test: Confirmed tuberculosis vs. those with possible tuberculosis or without
tuberculosis (n = 364).
CRP quotient Sensitivity Specificity
Positive
likelihood ratio
Negative
likelihood ratio
Diagnostic odds
ratio
Positive
predictive value
Negative
predictive value
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
.16ULN 0.97 0.4 1.62 0.07 22.0 0.49 0.96
(0.92; 0.99) (0.34; 0.47) (1.45; 1.81) (0.03; 0.20) (7.8; 61.6) (0.42; 0.55) (0.90; 0.99)
$2.56ULN 0.95 0.56 2.17 0.09 23.6 0.56 0.95
(0.90; 0.98) (0.50; 0.63) (1.86; 2.53) (0.04; 0.19) (10.5; 52.7) (0.49; 0.63) (0.90; 0.98)
$56ULN 0.88 0.67 2.66 0.18 14.9 0.61 0.90
(0.81; 0.93) (0.60; 0.73) (2.19; 3.22) (0.11; 0.28) (8.3: 27.0) (0.54; 0.68) (0.85; 0.94)
$106ULN 0.69 0.80 3.43 0.39 8.8 0.67 0.81
(0.60; 0.77) (0.74; 0.85) (2.59; 4.55) (0.30; 0.50) (5.4; 14.3) (0.58; 0.75) (0.76; 0.86)
doi:10.1371/journal.pone.0015248.t004
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patients experiencing the immune reconstitution inflammatory
syndrome after initiating antiretroviral therapy and the findings
from this study should not be extrapolated to these patients [25].
Finally, participants in this study were adult, had a Karnofsky
Score of $40; thus our findings cannot be extrapolated to
hospitalized patients or children.
In conclusion our data indicate that CRP could have a role in
sub-Saharan Africa in the evaluation of tuberculosis suspects who
are sputum smear-negative. CRP has the potential to contribute to
future algorithms for the primary care diagnosis of SNTB in high
HIV prevalence settings in combination with clinical evaluation.
The utility of point-of-care CRP in screening for SNTB should be
evaluated in primary care settings.
Supporting Information
Figure S1 Receiver operating curves and sensitivity/
specificity curves for confirmed TB vs. possible TB and
not TB: comparison between the two CRP assays. A
Initial 182 participants (confirmed TB n=43) using the Olympus
AU640 (normal range 0–8 mg/L); B Subsequent 182 participants
(confirmed TB n=92) using the Dade Dimension RXL (normal
range 0–5 mg/L).
(TIF)
Figure S2 Receiver operating curves and sensitivity/
specificity decision plots: intention to treat analysis (150
confirmed tuberculosis; 163 clinically diagnosed tuber-
culosis; 105 observed). A and B comparing participants with
confirmed tuberculosis vs. those with no tuberculosis (n = 255); C
and D combined confirmed and possible tuberculosis vs. those
with no tuberculosis (n = 418); and E and F confirmed tuberculosis
vs. those with possible tuberculosis and no tuberculosis (n = 418).
(TIF)
Table S1 Sensitivity and specificity for the comparison
confirmed TB vs. possible TB and not TB in HIV
seropositive participants (n=200).
(DOC)
Table S2 Sensitivity and specificity for the comparison
confirmed TB vs. possible TB and not TB in HIV
seronegative participants (n=39).
(DOC)
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